Resistant Hypertension Optimal Treatment

Hypertension Clinical Trial

— ReHOT  

Official title:

Multicenter Study of Patients With Hypertension Resistant to Patient Identification and Standardization of Therapeutic

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01643434
• Other study ID #: 0758/09
• Status: Recruiting
• Phase: Phase 4
• First received: July 11, 2012
• Last updated: June 6, 2013
• Start date: August 2012
• Est. completion date: July 2014

Study information

• Verified date: June 2013
• Source: Instituto do Coracao
• Contact: Eduardo M. Krieger, Doctor
• Phone: +55113069 5048
• Email: edkrieger[@]incor.usp.br
• Is FDA regulated: No
• Health authority: Brazil: National Committee of Ethics in Research
• Study type: Interventional

Clinical Trial Summary

Resistant hypertension (ReHy) is an emerging clinical and public health problem which tends to increase because populations are living longer and there is a growing global epidemic of obesity, diabetes and sleep apnea. It is also tempting to speculate that the excessive dietary salt ingestion reported in many countries can contribute substantially to the risk of ReHy development. ReHy is defined as persistent high blood pressure (above the target goal) in spite of the use of at least 3 antihypertensive agents of different classes, one of them must being diuretics.

Data regarding the exact prevalence of ReHy are very limited. In addition, little data is available about 3-drug combinations but a simplified treatment algorithm has demonstrated that a combination of a diuretic plus an angiotensin-converting enzyme inhibitors (ACEi) or an angiotensin-receptor blocker (ARB) plus diuretic, adding a calcium channel blocker when necessary, controlled 64% of hypertensive patients and, in addition, was even more efficient than the current guideline-based management. By contrast, the fourth drug to be added-on the triple regimen is still controversial and guided by empirical choices or personal preferences. Recent studies suggest the emerging role of spironolactone as the "first-line" fourth drug for treating resistant hypertension. Conversely, because of the pathophysiological rationale, others have proposed the use of β-blockers or even centrally acting agents for managing the sympathetic hyperactivity. The present concerns about the limited blood pressure reducing effect of β-blockers, especially in elderly people, the potent effect of centrally acting agents and our personal experience are pointing to clonidine as the fourth drug to be added-on to a multidrug combination for reaching optimal blood pressure in patients with ReHy. Nevertheless, no studies have been performed comparing, head-to-head, which one is the best fourth drug (spironolactone or clonidine) to be added-on to a common used multidrug combination in order to treat this condition.

Therefore, the principal objectives of the ReHOT Trial are to assess prospectively: (1) the prevalence of ReHy in a cohort of outpatients with stage II hypertension; (2) the effect of spironolactone on blood pressure, in comparison to clonidine, when added to a multidrug combination consisting of chlorthalidone plus ACEi (or ARB) plus amlodipine, all of 3 up-titrated to the highest dose; (3) the role of measuring sympathetic nervous system activity and renin-angiotensin-aldosterone activity on predicting the response of blood pressure to spironolactone and clonidine.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 2000
• Est. completion date: July 2014
• Est. primary completion date: December 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria

1. Patients aged between 18 and 75

2. With systolic blood pressure> 160 mmHg and <220mmHg and / or diastolic> 100 mmHg in the sitting position and according to Brazilian Guidelines on Hypertension (perform steps by obtaining two consecutive measurements differing by less than 4 mmHg between them, calibrated using a sphygmomanometer)

3. Patient regularly enrolled in participating center

Exclusion criteria

1. Systolic blood pressure> 220 mmHg

2. Patients with cardiovascular events (stroke, AMI, etc.). or cardiovascular procedures with less than 6 months of evolution

3. Renal stages IV and V (glomerular20 filtration estimated by MDRD formula <30 ml / min; where MDRD = 186 x (S_Cr) -1.154 x (age) -0.203 x (0.742 if fem.) x (1.210 if Afro-amer. ))

4. Heart failure class III and IV

5. History of malignant disease with life expectancy < 2 years

6. Alcoholism

7. Psychiatric illnesses that prevent compliance with the Protocol

8. Women of childbearing age who are not in use of effective contraception

9. Pregnancy

10. Arrhythmias, valvular heart disease, AV block 2 and 3 degrees without MP

11. Hepatic impairment

12. Patients with a history of hypersensitivity to any of the drugs under study

13. Examination of the fundus: Grade III and Grade IV

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Hypertension

Intervention

Drug:
• Spironolactone
Spironolactone (titrating dose from 12.5 to 50mg SID)
• Clonidine
Clonidine (titrating dose from 0.100-0.300mg BID)

Locations

Country	Name	City	State
Brazil	University of São Paulo General Hospital	São Paulo

Sponsors (2)

Lead Sponsor	Collaborator
Instituto do Coracao	Conselho Nacional de Desenvolvimento Científico e Tecnológico

Country where clinical trial is conducted

Brazil, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Blood pressure (mmHg)	Compare the effect of spironolactone on blood pressure vs. clonidine, when added to a multidrug combination consisting of chlorthalidone plus ACEi (or ARB) plus amlodipine, all of 3 up-titrated to the highest dose;	Patients willl be followed for an expected average of 3 months	Yes
Secondary	Sympathetic nervous system and renin-angiotensin-aldosterone activity	Compare the role of measuring sympathetic nervous system activity and renin-angiotensin-aldosterone activity on predicting the response of blood pressure to spironolactone and clonidine.	At baseline and at the end of the randomization (3 months)	No